Potential Shift in the Treatment Paradigm of Higher-Risk MDS with Magrolimab
Dr Hetty Carraway muses on whether magrolimab plus azacitadine will be used as a standard treatment for higher-risk MDS in the future.
EP: 1.An Overview of Myelodysplastic Syndrome (MDS)
EP: 2.The Progression of Myelodysplastic Syndrome to Acute Myeloid Leukemia (AML)
EP: 3.Risk Stratification for Patients with Myelodysplastic Syndrome
EP: 4.Treatment Goals for Patients with Myelodysplastic Syndrome
EP: 5.Currently Available Treatment Options for Patients with Higher-Risk Myelodysplastic Syndrome
EP: 6.Factors for Consideration when Choosing an Appropriate Treatment for Higher-Risk Myelodysplastic Syndrome
EP: 7.The Role of Allogeneic Stem Cell Transplant in Myelodysplastic Syndrome
EP: 8.The Role of Hypomethylating Agents (HMAs) in Higher-Risk Myelodysplastic Syndrome Treatment
EP: 9.Magrolimab plus Azacitidine for Myelodysplastic Syndrome
Now Viewing
EP: 10.Potential Shift in the Treatment Paradigm of Higher-Risk MDS with Magrolimab
EP: 11.Treating Patients with Myelodysplastic Syndrome and IDH or TP53 Mutations
EP: 12.Unmet Needs for Patients with Higher-Risk Myelodysplastic Syndrome
EP: 13.ENHANCE-2 Trial of Magrolimab plus Azacitidine in AML
EP: 14.ENHANCE-3 Trial of Magrolimab in Combination with Venetoclax and Azacitidine in AML
Recent Videos
Related Content
Treating the Patient With CML Who Is Pregnant or Trying to Become Pregnant
Martina Canichella, MD;Malgorzata Monika Trawinska, MD;Paolo De Fabritiis, MD;Elisabetta Abruzzese, MD, PhD
September 19th 2024Article
Careful management by a team of specialists is needed to balance disease control and fetal health in patients with CML who are pregnant or trying to become prengant.
Read More
